HOWL

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Werewolf Therapeutics and Ambros Therapeutics agreed to combine in an all-stock merger, alongside an oversubscribed $150 million private placement, to advance Ambros's neridronate program for CRPS-1. The setup shifts HOWL toward a newly financed, single-program clinical story, with deal terms, dilution and development execution becoming the key trading variables.